NYSE - Delayed Quote
USD
West Pharmaceutical Services, Inc. (WST)
412.62
-4.05
(-0.97%)
At close: October 30 at 4:00:03 PM EDT
412.62
0.00
(0.00%)
After hours: October 30 at 4:05:21 PM EDT
Trade WST on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for WST
What's happening with WST?
Powered by Yahoo ScoutWest Pharmaceutical Services delivered a stronger-than-expected third quarter, led by 16.6% organic growth in Proprietary Productsand rising demand for high-value components used in GLP-1 therapies. Management raised 2026 revenue and adjusted EPS guidance, while SmartDose divestiture and declining West Vantage sales create future growth offsets. WST is down 0.97% in the current regular sessionas of November 1, 2026.
Powered by Yahoo Scout
- Previous Close
416.67 - Open
419.06 - Bid 400.00 x 20000
- Ask 438.00 x 20000
- Day's Range
407.67 - 422.08 - 52 Week Range
223.83 - 438.27 - Volume
1,062,314 - Avg. Volume
571,970 - Market Cap (intraday)
28.744B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
52.83 - EPS (TTM)
7.81 - Earnings Date Oct 29, 2026
- Forward Dividend & Yield 1.04 (0.25%)
- 1y Target Est
445.33 - Morningstar Rating Rating available with Stock Picks access
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
WST
50.32%
S&P 500 (^GSPC)
10.73%
1-Year Return
WST
48.60%
S&P 500 (^GSPC)
11.11%
3-Year Return
WST
30.11%
S&P 500 (^GSPC)
81.91%
5-Year Return
WST
2.75%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
-
Market Cap
28.74B
-
Enterprise Value
28.58B
-
Trailing P/E
46.31
-
Forward P/E
42.41
-
PEG Ratio (current)
23.15
-
Price/Sales (ttm)
8.72
-
Price/Book (mrq)
9.70
-
Enterprise Value/Revenue
8.42
-
Enterprise Value/EBITDA
29.67
Financial Highlights
Profitability and Income Statement
-
Profit Margin
18.81%
-
Return on Assets (ttm)
11.93%
-
Return on Equity (ttm)
21.23%
-
Revenue (ttm)
3.4B
-
Net Income Avi to Common (ttm)
638.9M
-
Diluted EPS (ttm)
7.81
Balance Sheet and Cash Flow
-
Total Cash (mrq)
464.1M
-
Total Debt/Equity (mrq)
10.28%
-
Levered Free Cash Flow (ttm)
353.09M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
412.62
-0.97%
Mkt Cap
28.744B
Industry
Medical Instruments & Supplies
197.88
-0.23%
Mkt Cap
53.9B
Industry
Medical Instruments & Supplies
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
West Pharmaceutical Earnings: High-Quality Growth and Margin Support Another Guidance Raise
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
-
Raising target price to $438.00
West Pharmaceutical Services Inc has an Investment Rating of BUY; a target price of $438.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
-
Raising target price to $428.00
West Pharmaceutical Services Inc has an Investment Rating of BUY; a target price of $428.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
-
West Pharmaceutical's Long-Term Growth Intact
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
